Proton pump inhibitors: actions and reactions.
Proton pump inhibitors are the second most commonly prescribed drug class in the United States. The increased utilization of PPIs parallels the rising incidence of reflux disease. Owing to their clinical efficacy and relative lack of tachyphylaxis, PPIs have largely displaced H-2 receptor antagonists in the treatment of acid peptic disorders. The elevation of intragastric pH and subsequent alterations of gastric physiology induced by PPIs may yield undesired effects within the upper GI tract. The ubiquity of the various types of H(+), K(+)-ATPase could also contribute to non-gastric effects. PPIs may influence physiology in other ways, such as inducing transepithelial leak.
Mullin
James M
JM
Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096-3450, USA. MullinJ@MLHS.org
Gabello
Melissa
M
Murray
Lisa J
LJ
Farrell
Christopher P
CP
Bellows
Jillan
J
Wolov
Kevin R
KR
Kearney
Keith R
KR
Rudolph
David
D
Thornton
James J
JJ
D000818:Animals; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D054328:Proton Pump Inhibitors / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use*
D054328:Proton Pump Inhibitors